Pacira生物科學 PCRX 深 滬
已收盤 07-02 16:00:00 美东时间
25.39
+0.360
+1.44%
華盛通- 最 高25.55
- 今 開25.14
- 成交量 37.05万股
- 最 低 24.43
- 昨 收 25.03
- 總市值 9.99亿
- 52周最高 27.64
- 市盈率 靜 162.55
- 換手率 0.94%
- 52周最低 18.80
- 委 比 55.73%
- 總股本 3934.79万
- 歷史最高 121.95
- 量 比 0.62
- 振 幅 4.47%
- 歷史最低 6.51
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $38 price target.
07-01 20:15
骨科巨头Zimmer1.4亿美元收购术后冷冻镇痛器械
（来源：MedTF医瞰科技） 骨科医疗器械巨头捷迈邦美（Zimmer Biomet，NYSE: ZBH）与Pacira BioSciences&n...
07-01 19:30
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare now provides separate reimbursement for EXPAREL across outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This update enables EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members, representing an additional step in expanding access to non-opioid postsurgical pain management options. With approximately 40 million ...
07-01 12:00
Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140M
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of iovera ®° to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader. Th...
06-30 19:36
Pacira BioSciences SVP Finance Lauren Riker sells 6,115 shares for $143,702.5
Pacira BioSciences SVP Finance Lauren Riker sells 6,115 shares for $143,702.5 Pacira BioSciences SVP of Finance Lauren Riker sold 6,115 common shares on June 11 at USD 23.5 each. Riker held 62,284 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT)
06-13 09:08
Pacira Biosciences director Thomas G. Wiggans files initial beneficial ownership statement
Pacira Biosciences director Thomas G. Wiggans files initial beneficial ownership statement Pacira BioSciences director Thomas G. Wiggans filed an initial Form 3 disclosure dated June 9, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligen
06-13 09:06
Pacira shareholders lobbied by hedge fund board nominees
Shareholders of Pacira BioSciences (PCRA) have been told by two individuals backed by DOMA Perpetual Capital Management to join the biopharma's board to ignore criticisms of them by management and ele...
05-22 02:41
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), ...
05-22 01:53
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive Change Intend to Work Collaboratively ...
05-21 00:28
